Back to Results

China Shineway Pharmaceutical Group Ltd ADR (CSWYY)

China Shineway Pharmaceutical Group Ltd is a depositary receipt listed on OTC Markets, tied to China Shineway Pharmaceutical Group Limited. The issuer is an investment holding company focused on the research, production, and trading of Chinese pharmaceutical products in mainland China and Hong Kong. Its portfolio includes medicines distributed in forms such as injections, soft capsules, granules, tablets, pills, oral liquids, and powders, along with traditional Chinese medicine granules used across therapeutic areas including respiratory, nervous system, digestive, cardiovascular and cerebrovascular, orthopedics, and pediatrics. The company also trades agricultural products. Incorporated in 2002 and headquartered in Shijiazhuang, China, the issuer is a subsidiary of Forway Investment Limited.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Payment Date Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio
OTC-CSWY.Y
$25.78
20.0% Upside
Undervalued
Not available
Not available
Great
October 15, 2026
18.3%
November 27, 2026
6.6x
0.6x
2.0x
788.3 M
-271 M
5.0%
27.4%
11.9
37.4%
Valuation • Fair Value

China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) Fair Value by Valuation Model

Review the available estimates for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$25.78

Estimated upside of 20.0% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$33.18

Discounted cash flow valuation reference.

Ben Graham Formula Value

$29.67

Classic Ben Graham valuation formula reference.

Comps Fair Value

$20.85

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 5 available valuation references for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

392.3 M

Current operating scale indicator.

Revenue Forecast

349.8 M

Forward revenue estimate.

EBITDA

97.654 M

Current operating profitability reference.

EBITDA Forecast

121.3 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

-1.98

Intermediate zone that deserves monitoring.

Altman Z-Score

11.9

Relatively strong balance-sheet zone.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 27, 2026

Days to Earnings

66

Dividend Payment Date

October 15, 2026

Dividend Yield

18.3%

Current income yield reference.

Payout Ratio

37.4%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Neutral

The monthly technical read for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) Stock FAQ

Data-supported answers about China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$25.78
Estimated upside 20.0%
Valuation Rating
Undervalued
Estimated upside of 20.0%
Financial Health
Great
Current financial-health read

The current fair value estimate for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is $25.78. This implies an estimated upside of 20.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 20.0% versus the current market price.

The current financial health read for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is November 27, 2026.

Based on the current data, dividend yield is 18.3%, payment date is October 15, 2026.

The current P/E ratio listed for China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is 6.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for China Shineway Pharmaceutical Group Ltd ADR is 788.3 M.

The current enterprise value listed for China Shineway Pharmaceutical Group Ltd ADR is -271 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for China Shineway Pharmaceutical Group Ltd ADR is OTC-CSWY.Y, and the stock is listed on OTC Markets.

China Shineway Pharmaceutical Group Ltd ADR (OTC-CSWY.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for China Shineway Pharmaceutical Group Ltd ADR is 5.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for China Shineway Pharmaceutical Group Ltd ADR is 27.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B